GalenicaGLLNY 80 EBITDA Margin % is 8.53% as of Dec. 2025, which is 5% above its 10-year median of 8.10. GuruFocus rates GLLNY with a GF Score™ of 80/100. The stock has 1 warning sign investors should review. Among 119 Medical Distribution companies, Galenica ranks better than 67.23% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Galenica's EBITDA for the
six
months ended in Dec. 2025 was $229.11 Mil. Galenica's Revenue for the
six
months ended in Dec. 2025 was $2,685.73 Mil. Therefore, Galenica's EBITDA margin for the quarter that ended in Dec. 2025 was 8.53%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Galenica EBITDA Margin % Related Terms
Galenica EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Galenica's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLLNY vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Galenica's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galenica EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Galenica's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Galenica's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galenica (GLLNY) has a EBITDA Margin % of 8.53% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Galenica and its competitors. This is near median its historical median of 8.10. Over the past decade, Galenica's EBITDA Margin % has ranged from 4.89 to 8.91. According to the industry distribution chart, Galenica ranks #39 out of 119 companies in the Medical Distribution industry, placing it in the top 32.8%.
Is Galenica's EBITDA Margin % too high?
Galenica's current EBITDA Margin % of 8.53% is near median its 10-year median of 8.10. Over the past 10 years, this metric has ranged from a low of 4.89 to a high of 8.91. The Medical Distribution industry median EBITDA Margin % is 4.31. Galenica's value of 8.53% is 97.9% above this industry median. Based on the distribution chart, Galenica ranks #39 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Galenica has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Galenica's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Galenica ranks #39 out of 119 companies for EBITDA Margin %. This puts Galenica in the upper half of its industry. The industry median EBITDA Margin % is 4.31. Galenica's value of 8.53% is 97.9% above this benchmark. Historically, Galenica's own EBITDA Margin % has ranged from 4.89 to 8.91 over the past decade. While the company's 10-year median is 8.10 vs. the industry median of 4.31, Galenica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galenica's current EBITDA Margin % of 8.53% is 97.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Galenica and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galenica's current EBITDA Margin % is 8.53%, which is near median its own 10-year median of 8.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galenica stock overvalued right now?
Galenica (GLLNY) has a current EBITDA Margin % of 8.53%. The current EBITDA Margin % is 8.53%, which is near median its 10-year median of 8.10 and 97.9% above the Medical Distribution industry median of 4.31. Galenica's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Galenica (GLLNY), the current EBITDA Margin % is 8.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galenica Ltd is an integrated healthcare service provider in Switzerland. The business is operated from two segments Products & Care and Logistics & IT. The Products & Care segment comprises the Retail business area with offerings for patients and end customers and the Professionals business area with offerings for business customers and partners in the healthcare sector. The Logistics & IT segment comprises the two sectors Wholesale and Logistics & IT Services. These provide services for all those involved in the healthcare sector - pharmacies, drugstores, doctors, hospitals and care homes, partners, and suppliers. Geographically, it operates in Switzerland and Other Countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLLNY has been successfully added to your 